Nuwellis pediatric segment reaches 50% of total US revenue in 2025
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil gains after Trump says US will hit Iran 'very hard tonight'
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
Nuwellis Pediatric Category Achieves Approximately 50% of Total U.S. Revenue in 2025, Marking Growth Milestone
March 31, 2026 8:30 AM EDTMINNEAPOLIS, March 31, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces continued momentum in its pediatric category, which is now the Companys largest and fastest-growing category and represents approximately 50% of total U.S. revenue.
Our pediatric category has become a meaningful and durable driver of growth, now accounting for approximately half of total revenue in 2025. This is a significant milestone as it both demonstrates the importance of the pediatric utilization of Aquadex, and the flexibility of the device across multiple patient... More
